Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: TXG

10x Genomics, Inc.

Healthcare | Medical - Healthcare Information Services

No licensed closing price on file for TXG. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-0.59

10x Genomics, Inc. (NASDAQ: TXG) is a health information company. Figures from SEC EDGAR; updated 2026-10-20 07:47 UTC.

What 10x Genomics, Inc. does

This life sciences technology company develops instruments, consumables, and software for analyzing biological systems at the cellular and tissue level. The company's product portfolio includes the Chromium platform for single-cell analysis, the Visium platform for spatial analysis, and the Xenium platform for in situ gene expression detection, along with supporting software tools. Customers include academic researchers, translational researchers, and biopharmaceutical companies worldwide.

Summarized from 10x Genomics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-0.59

Revenue, margins & earnings

FY2021: net loss $58M on revenue $490M$490MFY2021FY2022: net loss $166M on revenue $516M$516MFY2022FY2023: net loss $255M on revenue $619M$619MFY2023FY2024: net loss $183M on revenue $611M$611MFY2024FY2025: net loss $44M on revenue $643M$643MFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
  • Net loss year
Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-24
  • 2026-09-24Chief Executive OfficerSale-9,900$810.1K
  • 2026-09-24DirectorSale-2,270$185.4K
  • 2026-09-24Chief Executive OfficerSale-1,000$78.2K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does 10x Genomics, Inc. do?

This life sciences technology company develops instruments, consumables, and software for analyzing biological systems at the cellular and tissue level.

When did TXG last file with the SEC?

10x Genomics, Inc.'s most recent SEC filing on record is a SCHEDULE 13G/A filed 2026-10-07. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 07:47 UTC. This page is also available as JSON at /api/data?ticker=TXG and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for TXG and 5,000+ tickers.

Create a free account — keep TXG
For your agent
GET /api/data?ticker=TXG

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt